Rocket Fast Germination Technology

… Quick Activation that Leaves Everyone Else in the Dust

Spore forming bacteria— especially strong Bacillus species— have some of the broadest collection of tools to employ in transforming nutrients and expanding growth in its environment. Bacillus species produce enzymes, amino acids, organic acids, proteins, bacteriocins, and antibiotics. When compared to other types of bacteria used in commercial applications Bacillus species are a veritable “Swiss Army Knife” in breadth and utility.

Speed

When compared to Lactobacillus and Bifidobacteria species in probiotics, or Pseudomonas in crop production applications, Bacillus species have distinct advantage via spectrum and storage stability. Historically the sole negative aspect of Bacillus has been slow germination and attaining the operative vegetative state. Speed of activity is crucial for competitive exclusion of other bacteria and achieving logarithmic growth to maximize performance. Rocket Fast Germination™ Technology (RFGT) enables spores to germinate in 5 to 15 minutes versus hours with current commercial spores.

Rocket Fast Germination Technology Transitions Spore Lag Phase

The development of RFGT allows MicroSynergies’ production partners to produce ready-to-use spores which are enabled to quickly germinate when introduced to target environments. The spores can be formulated or topically mixed into feed sources for probiotic use, or used as seed treatment, granule or spray application for agricultural production. The graphs to the right exhibit the differential effect from utilizing RFGT spores versus the same strain spores without the technology. Equivalent results have been achieved across multiple spore forming species.

MicroSynergies LLC is the world leader in sourcing for the largest collection of commercial microbial ingredients on the planet. Through our agreements, partnerships, and network of global microbial manufacturers, we connect our customers to thousands of strains in formats including bulk cultures, concentrates, contract fermentations, and specialty biologicals and market them under our proprietary brand names. In many of these formats, we’re able to include our value-added MicroSynergy™ technology for creating enhanced stability, longer shelf-life, and increased activity post-production. From there, we can augment our offerings with expert formulation and technical support, market access, our award-winning 3+80™ supply risk guarantee, and microbial-specific marketing expertise. All information and data supplemented by data and visuals are independently verified, current, and correct to the best of our knowledge. For more information, contact your MicroSynergies representative.

In 2016— in association with one of our key partners— we added a unique group of proprietary and patented low temperature growing bacteria to our offerings.

The psychrophilic microorganisms are naturally occurring bacteria isolated from a stream in the USA with the ability to grow at 4°C or below. A colleague elaborated,

“The feedback on the performance of these patented strains has been phenomenal… [a] client obtained excellent results treating a wastewater treatment system that was at 1.7°C, where competitors’ products had failed. This is further validation that [our] approach of isolating unique organisms targeted at addressing specific issues results in real world solutions for our customers… We are continuing to build our proprietary microbial collection, and we have raised the bar on what it takes to be a top performer in this field.”

The bacteria covered in the awarded patent are listed as Bacillus sp. The taxonomic decision was made because the bacteria do not match well to any existing species. Genetic analysis using 16S ribosomal RNA indicated the closest matches were Bacillus simplex or Bacillus butanolivorans. Further testing in the laboratory revealed some major biochemical differences between the newly isolated strains and the B. simplex and B. butanolivorans types.

The graph to the right illustrates the metabolic activity of the C2B2 Cold Conditions Bacteria Blend™ at 4°C in a respirometer. The data are reported as change in biochemical oxygen demand (BOD).

As is shown, the patented strains quickly germinate, and grow at 4°C, reducing the amount of waste in the system, while the competitive product does not show any metabolic activity.

Our C2B2 partner is a bioscience-based company focused on the production of environmentally friendly products. With decades of experience in the isolation, large scale production, stabilization and product formulation of microorganisms, they are a leader in the development and commercialization of microbial and enzyme-based products for the consumer, institutional, agricultural, wastewater, and bioremediation markets. Their technology platform includes expertise in the areas of bacteriology, mycology, enzymology, and chemistry.

Roy Glocke Founder & Chief Technical Advisor MicroSynergies